SYDNEY-BASED pharmaceutical
company Phebra has announced
the PBS listing of its Phenasen
(arsenic trioxide) injection for
the first line treatment of newly
diagnosed acute promyelocytic
leukaemia (APL).
The rare disease has an incidence
rate of 2-3 patients per every 1
million people, with Phebra ceo
Mal Eutick saying the expanded
listing now provides for treatment
of newly diagnosed sufferers
as well as those with relapsed/
refractory disease.
Eutick said Phenasen had
been developed by Phebra in
collaboration with several top
Australian haematologists, with
the product manufactured in the
company’s Lane Cove West facility.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Apr 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.